Li T, Wu Z, Jiang M, et al. - Given the Roche Cobas (Cobas) and BD Onclarity (Onclarity) human papillomavirus (HPV) assays represent convenient, PCR-based, HPV DNA tests, researchers assessed the clinical performance of Onclarity for identifying cervical lesions in Chinese women. This study included 1,122 women. Experts obtained exfoliated cervical cells in the PreservCyt medium and examined those using Cobas and Onclarity. At Cancer Hospital, Chinese Academy of Medical Sciences, senior cytologists interpreted cytology and a panel of pathologists interpreted histology. They found excellent concordance for HPV16 and for 12 other high-risk types (HPV31/33/35/39/45/51/52/56/58/59/66/68) was displayed by the assays. Also, the assays showed very good concordance for HPV18. Based on the findings, it was concluded that the screening performance and triage efficiency of Onclarity are comparable to that of Cobas in the detection of cervical lesions in Chinese women.